Vandetanib(LuciVande)

Vandetanib was first approved in the United States in 2011, and the latest revision of its prescribing information was in May 2025.

Indicated Population

Indicated for adult patients with confirmed unresectable locally advanced or metastatic medullary thyroid cancer.

Dosage and Administration

The standard recommended dose is 300 mg orally once daily, with or without food; dosage adjustment may be required based on toxicity or the patient's renal function. Reference article: Dosage and Administration of Vandetanib

Use in Specific Populations

The starting dose requires adjustment in patients with moderate renal impairment; it is not recommended for patients with severe hepatic or renal impairment; men and women of reproductive potential, pregnant women, and breastfeeding women must strictly observe contraception and breastfeeding restrictions.

Overdosage

In case of overdose, closely monitor the QTc interval on electrocardiogram, as its long half-life may prolong the effects.

Pharmacokinetics

The drug is slowly absorbed after oral administration, has a long half-life of approximately 19 days, and steady-state plasma concentrations are reached in about 3 months; it is primarily excreted slowly in feces and urine.